Edwards Lifesciences (NYSE:EW) PT Raised to $88.00 at Piper Sandler

Edwards Lifesciences (NYSE:EW) had its price objective increased by research analysts at Piper Sandler from $85.00 to $88.00 in a note issued to investors on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the medical research company’s stock. Piper Sandler’s target price would indicate a potential upside of 1.30% from the stock’s current price.

EW has been the topic of several other research reports. Citigroup lifted their price target on Edwards Lifesciences from $90.00 to $98.00 and gave the company a “neutral” rating in a research note on Wednesday, April 3rd. Stifel Nicolaus increased their target price on shares of Edwards Lifesciences from $70.00 to $83.00 and gave the stock a “hold” rating in a report on Wednesday, February 7th. Morgan Stanley boosted their price target on shares of Edwards Lifesciences from $95.00 to $103.00 and gave the stock an “overweight” rating in a research report on Thursday, March 21st. StockNews.com cut Edwards Lifesciences from a “buy” rating to a “hold” rating in a report on Wednesday, March 20th. Finally, OTR Global raised Edwards Lifesciences from a “mixed” rating to a “positive” rating in a research report on Tuesday, March 26th. One analyst has rated the stock with a sell rating, seven have assigned a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $93.07.

Edwards Lifesciences Trading Down 1.3 %

Shares of EW stock traded down $1.14 on Friday, reaching $86.87. The company had a trading volume of 1,682,411 shares, compared to its average volume of 3,799,203. The company has a 50-day moving average of $90.27 and a 200-day moving average of $78.76. The company has a current ratio of 3.38, a quick ratio of 2.40 and a debt-to-equity ratio of 0.09. The stock has a market cap of $52.29 billion, a PE ratio of 37.49, a PEG ratio of 4.39 and a beta of 1.05. Edwards Lifesciences has a 12 month low of $60.57 and a 12 month high of $96.12.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings results on Thursday, April 25th. The medical research company reported $0.66 EPS for the quarter, topping analysts’ consensus estimates of $0.64 by $0.02. Edwards Lifesciences had a return on equity of 23.56% and a net margin of 23.35%. The company had revenue of $1.60 billion for the quarter, compared to analyst estimates of $1.58 billion. On average, equities analysts forecast that Edwards Lifesciences will post 2.76 earnings per share for the current year.

Insider Buying and Selling at Edwards Lifesciences

In other news, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the sale, the chief financial officer now owns 19,248 shares of the company’s stock, valued at $1,506,925.92. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. In other news, Director Michael A. Mussallem sold 29,350 shares of the company’s stock in a transaction on Thursday, April 4th. The stock was sold at an average price of $92.42, for a total transaction of $2,712,527.00. Following the completion of the sale, the director now directly owns 4,486 shares in the company, valued at approximately $414,596.12. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, CFO Scott B. Ullem sold 7,255 shares of the business’s stock in a transaction dated Thursday, February 1st. The shares were sold at an average price of $78.29, for a total value of $567,993.95. Following the completion of the transaction, the chief financial officer now directly owns 19,248 shares of the company’s stock, valued at approximately $1,506,925.92. The disclosure for this sale can be found here. Insiders have sold a total of 194,004 shares of company stock valued at $17,166,254 in the last ninety days. 1.29% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Edwards Lifesciences

Hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Edwards Lifesciences by 1.4% in the fourth quarter. Vanguard Group Inc. now owns 52,363,400 shares of the medical research company’s stock valued at $3,992,709,000 after acquiring an additional 729,984 shares during the last quarter. Bank of New York Mellon Corp increased its stake in shares of Edwards Lifesciences by 9.5% in the 1st quarter. Bank of New York Mellon Corp now owns 18,973,304 shares of the medical research company’s stock valued at $1,813,089,000 after purchasing an additional 1,644,869 shares during the last quarter. Brown Advisory Inc. raised its holdings in shares of Edwards Lifesciences by 20.1% during the 4th quarter. Brown Advisory Inc. now owns 18,181,420 shares of the medical research company’s stock worth $1,386,333,000 after buying an additional 3,048,274 shares in the last quarter. Wellington Management Group LLP lifted its position in shares of Edwards Lifesciences by 2.4% during the 4th quarter. Wellington Management Group LLP now owns 16,827,510 shares of the medical research company’s stock worth $1,283,098,000 after buying an additional 393,109 shares during the last quarter. Finally, Norges Bank acquired a new stake in Edwards Lifesciences in the fourth quarter valued at about $648,540,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.